

Government of the District of Columbia Department of Health



899 NORTH CAPITOL ST. NE – 2ND FLR. WASHINGTON, DC 20002

February 1, 2018

9:30am- 11:30 am

OPEN SESSION AGENDA

Board of Pharmacy Mission Statement:

"To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians."

DR .DAPHNE B. BERNARD, PHARM.D. R.PH CHAIRPERSON	
DR. BENJAMIN MILES PHARM.D. R.PH	
Mr. Alan Friedman, R.PH	
Mr. Eddie Curry, consumer member	
Shauna White– Executive Director	
KARIN BARRON-HEALTH LICENSING SPECIALIST	
LATASHA GASKIN, HEALTH LICENSING SPECIALIST	
·	
CARLA WILLIAMS. ASSISTANT GENERAL COUNSEL	
	MR. ALAN FRIEDMAN, R.PH MR. EMMANUEL BELLEGARDE, CONSUMER MEMBER MR. EDDIE CURRY, CONSUMER MEMBER SHAUNA WHITE—EXECUTIVE DIRECTOR

CALL TO ORDER:

PRESIDING:

Open Session Agenda

Quorum:

	20010111.	
Introduction:		
0201-0-01	Approval of the Open Session Meeting Minutes	
	December 7, 2017 January 4 th , 2018	
Consent Agenda	None	
Executive Director Report	Licensing Report Statistics Pharmaceutical Detailer Renewal NABP Updates	
Assistant General Counsel Report		Carla Williams
0201-0-02	Defending Access to Woman's Health Care Services Amendment Act of 2017	
0201-0-03	Opioid Abuse Prevention Amendment Act of 2017	
Subcommittee Report		
	Legislative and Regulatory	
0201-0-04	Collaborative Practice Agreement	Mr. Alan Friedman
0201-O-05	Communications Subcommittee Report	Dr. Daphne Bernard
0201-0-06	NABP News Presentation	Bini Mathew
NABP E- Newsletter	January 24, 2018 NABP E-News	
INEMPIERRE	Twitter Cites NABP Verification as Requirement for Pharmacy Advertising	
	FDA Issues 2018 Compounding Priorities Plan and Three Final Guidances Related to DQSA	
	Pharmacy Stakeholders Worldwide to Discuss Transforming Patient	

	Outcomes During 2018 FIP Congress	
	FDA to Alert Public of Recalls Sooner	
	Extension of Shelf Life Provided by Baxter to Assist with IV Solution Shortages	
	USP Encourages Pharmacists to Help Patients Find Quality Dietary Supplements	
	January 17, 2018 NABP E-News	
	NABP Launching Upgraded e-Profile System April 2, 2018	
	State-approved Telehealth Laws Became Effective January 1, 2018	
	Department of Veterans Affairs Publicly Posts Opioid Prescribing and Dispensing Data	
	FDA Requires Labeling Update on Opioid-Containing Medicines to Treat Cough and Cold for Children and Adults	
	International Laboratories Issue Nationwide Recall of One Lot of Clopidogrel Tablets Due to Mislabeling	
	PTCB Updates Certification Exam Outline and Requirements for Education and Training	
	Upcoming FDA Webinar to Discuss FAERS Public Dashboard	
Matters for Board Consideration	None	
Comments from the Public		
Motion to Adjourn the Open Session	Madam Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4);	
	(Roll Call Vote)	
1		

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the reasons set forth in the motion.

Open Session Meeting Adjourned at __:_